ANEBULO PHARMACEUTICALS, INC. Operating Expenses
ANEBULO PHARMACEUTICALS, INC. (ANEB) reported Operating Expenses of $2.62 million for the 3-month period ending 2025-12-31, per its 10-Q filed 2026-02-12.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingExpenses · last filed 2026-02-12
- ANEBULO PHARMACEUTICALS, INC. operating expenses for the quarter ending 2025-12-31 was $2.62M, a 1.23% increase year-over-year.
- ANEBULO PHARMACEUTICALS, INC. operating expenses for the quarter ending 2025-09-30 was $2.26M, a 6.30% decline year-over-year.
- ANEBULO PHARMACEUTICALS, INC. operating expenses for the quarter ending 2025-06-30 was $2.33M, a 73.90% increase year-over-year.
- ANEBULO PHARMACEUTICALS, INC. operating expenses for the quarter ending 2025-03-31 was $1.89M, a 13.70% increase year-over-year.
- ANEBULO PHARMACEUTICALS, INC. operating expenses for fiscal 2025 was $9.22M, a 11.01% increase from fiscal 2024.
- ANEBULO PHARMACEUTICALS, INC. operating expenses for fiscal 2024 was $8.31M, a 29.49% decline from fiscal 2023.
- ANEBULO PHARMACEUTICALS, INC. operating expenses for fiscal 2023 was $11.78M, a 72.50% increase from fiscal 2022.
- ANEBULO PHARMACEUTICALS, INC. operating expenses for fiscal 2022 was $6.83M, a 89.03% increase from fiscal 2021.
| Period end | Operating Expenses 2 month | Operating Expenses 3 month | Operating Expenses 6 month | Operating Expenses 9 month | Operating Expenses 12 month |
|---|---|---|---|---|---|
| 2025-12-31 | $2.62M 10-Q · filed 2026-02-12 | $4.88M 10-Q · filed 2026-02-12 | $7.21M derived: sum of 3 quarters · filed 2026-02-12 | $9.10M derived: sum of 4 quarters · filed 2026-02-12 | |
| 2025-09-30 | $2.26M 10-Q · filed 2025-11-13 | $4.59M derived: sum of 2 quarters · filed 2025-11-13 | $6.48M derived: sum of 3 quarters · filed 2025-11-13 | $9.07M derived: sum of 4 quarters · filed 2026-02-12 | |
| 2025-06-30 | $2.33M derived: 10-K 12 month − 10-Q 9 month · filed 2025-09-29 | $4.22M derived: sum of 2 quarters · filed 2025-09-29 | $6.81M derived: sum of 3 quarters · filed 2026-02-12 | $9.22M 10-K · filed 2025-09-29 | |
| 2025-03-31 | $1.89M 10-Q · filed 2025-05-13 | $4.48M derived: sum of 2 quarters · filed 2026-02-12 | $6.89M 10-Q · filed 2025-05-13 | $8.23M derived: sum of 4 quarters · filed 2026-02-12 | |
| 2024-12-31 | $2.59M 10-Q · filed 2026-02-12 | $5.00M 10-Q · filed 2026-02-12 | $6.34M derived: sum of 3 quarters · filed 2026-02-12 | $8.00M derived: sum of 4 quarters · filed 2026-02-12 | |
| 2024-09-30 | $2.41M 10-Q · filed 2025-11-13 | $3.75M derived: sum of 2 quarters · filed 2025-11-13 | $5.42M derived: sum of 3 quarters · filed 2025-11-13 | $8.18M derived: sum of 4 quarters · filed 2025-11-13 | |
| 2024-06-30 | $1.34M derived: 10-K 12 month − 10-Q 9 month · filed 2025-09-29 | $3.00M derived: sum of 2 quarters · filed 2025-09-29 | $5.77M derived: sum of 3 quarters · filed 2025-09-29 | $8.31M 10-K · filed 2025-09-29 | |
| 2024-03-31 | $1.66M 10-Q · filed 2025-05-13 | $4.42M derived: sum of 2 quarters · filed 2025-05-13 | $6.97M 10-Q · filed 2025-05-13 | $9.46M derived: sum of 4 quarters · filed 2025-05-13 | |
| 2023-12-31 | $2.76M 10-Q · filed 2025-02-14 | $5.30M 10-Q · filed 2025-02-14 | $7.80M derived: sum of 3 quarters · filed 2025-02-14 | $10.66M derived: sum of 4 quarters · filed 2025-02-14 | |
| 2023-09-30 | $2.54M 10-Q · filed 2024-11-13 | $5.04M derived: sum of 2 quarters · filed 2024-11-13 | $7.90M derived: sum of 3 quarters · filed 2024-11-13 | $11.72M derived: sum of 4 quarters · filed 2024-11-13 | |
| 2023-06-30 | $2.49M derived: 10-K 12 month − 10-Q 9 month · filed 2024-09-25 | $5.36M derived: sum of 2 quarters · filed 2024-09-25 | $9.17M derived: sum of 3 quarters · filed 2024-09-25 | $11.78M 10-K · filed 2024-09-25 | |
| 2023-03-31 | $2.86M 10-Q · filed 2024-05-15 | $6.68M derived: sum of 2 quarters · filed 2024-05-15 | $9.29M 10-Q · filed 2024-05-15 | $11.61M derived: sum of 4 quarters · filed 2024-05-15 | |
| 2022-12-31 | $3.81M 10-Q · filed 2024-02-13 | $6.43M 10-Q · filed 2024-02-13 | $8.75M derived: sum of 3 quarters · filed 2024-02-13 | $10.63M derived: sum of 4 quarters · filed 2024-02-13 | |
| 2022-09-30 | $2.61M 10-Q · filed 2023-11-14 | $4.94M derived: sum of 2 quarters · filed 2023-11-14 | $6.82M derived: sum of 3 quarters · filed 2023-11-14 | $7.89M derived: sum of 4 quarters · filed 2023-11-14 | |
| 2022-06-30 | $2.33M derived: 10-K 12 month − 10-Q 9 month · filed 2023-09-22 | $4.21M derived: sum of 2 quarters · filed 2023-09-22 | $5.28M derived: sum of 3 quarters · filed 2023-09-22 | $6.83M 10-K · filed 2023-09-22 | |
| 2022-03-31 | $1.88M 10-Q · filed 2023-05-11 | $2.95M derived: sum of 2 quarters · filed 2023-05-11 | $4.51M 10-Q · filed 2023-05-11 | $6.99M derived: sum of 4 quarters · filed 2023-05-11 | |
| 2021-12-31 | $1.07M 10-Q · filed 2023-02-10 | $2.63M 10-Q · filed 2023-02-10 | $5.11M derived: sum of 3 quarters · filed 2023-02-10 | $5.66M derived: sum of 4 quarters · filed 2023-02-10 | |
| 2021-09-30 | $1.55M 10-Q · filed 2022-11-10 | $4.04M derived: sum of 2 quarters · filed 2022-11-10 | $4.59M derived: sum of 3 quarters · filed 2022-11-10 | $4.92M derived: sum of 4 quarters · filed 2022-11-10 | |
| 2021-06-30 | $2.48M derived: 10-K 12 month − 10-Q 9 month · filed 2022-09-09 | $3.04M derived: sum of 2 quarters · filed 2022-09-09 | $3.36M derived: sum of 3 quarters · filed 2022-09-09 | $3.61M 10-K · filed 2022-09-09 | |
| 2021-03-31 | $552.13K 10-Q · filed 2022-05-11 | $876.70K derived: sum of 2 quarters · filed 2022-05-11 | $1.13M 10-Q · filed 2022-05-11 | ||
| 2020-12-31 | $324.57K 10-Q · filed 2022-02-11 | $576.92K 10-Q · filed 2022-02-11 | |||
| 2020-09-30 | $252.35K 10-Q · filed 2021-11-12 | ||||
| 2020-06-30 | $173.35K 10-K · filed 2021-09-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ACTUATE THERAPEUTICS, INC. (ACTU) | United States | $0.015B | |
| Lantern Pharma Inc. (LTRN) | United States | $0.015B | -2.87 |
| Citius Pharmaceuticals, Inc. (CTXR) | United States | $0.016B | -133.06 |
| Tvardi Therapeutics, Inc. (TVRD) | United States | $0.014B | |
| Vyome Holdings, Inc (HIND) | United States | $0.014B | -1.38 |
| Korsana Biosciences, Inc. (CYCN) | United States | $0.016B | |
| BullFrog AI Holdings, Inc. (BFRG) | United States | $0.014B | |
| LISATA THERAPEUTICS, INC. (LSTA) | United States | $0.014B | -2.13 |
| Pasithea Therapeutics Corp. (KTTA) | United States | $0.017B | -0.81 |
| Vistagen Therapeutics, Inc. (VTGN) | United States | $0.013B | -0.14 |